[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1116004T1 - Παραγωγα οξαζολυλ-μεθυλαιθερα ως αγωνιστες υποδοχεα alx - Google Patents

Παραγωγα οξαζολυλ-μεθυλαιθερα ως αγωνιστες υποδοχεα alx

Info

Publication number
CY1116004T1
CY1116004T1 CY20151100075T CY151100075T CY1116004T1 CY 1116004 T1 CY1116004 T1 CY 1116004T1 CY 20151100075 T CY20151100075 T CY 20151100075T CY 151100075 T CY151100075 T CY 151100075T CY 1116004 T1 CY1116004 T1 CY 1116004T1
Authority
CY
Cyprus
Prior art keywords
oxazolyl
methyl
receptor agonists
ethyl derivative
alx receptor
Prior art date
Application number
CY20151100075T
Other languages
English (en)
Inventor
Daniel Bur
Olivier Corminboeuf
Sylvaine Cren
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of CY1116004T1 publication Critical patent/CY1116004T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση σχετίζεται με παράγωγα οξαζολυλ-μεθυλαιθέρα του χημικού τύπου (I), όπου τα R1, R2, R3, R4, και R5 είναι όπως ορίστηκαν στην περιγραφή, με την παρασκευή και τη χρήση τους ως φαρμακευτικά δραστικές ενώσεις.
CY20151100075T 2010-12-07 2015-01-23 Παραγωγα οξαζολυλ-μεθυλαιθερα ως αγωνιστες υποδοχεα alx CY1116004T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2010055616 2010-12-07
EP11804810.7A EP2649068B1 (en) 2010-12-07 2011-12-06 Oxazolyl-methylether derivatives as alx receptor agonists

Publications (1)

Publication Number Publication Date
CY1116004T1 true CY1116004T1 (el) 2017-01-25

Family

ID=45444667

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100075T CY1116004T1 (el) 2010-12-07 2015-01-23 Παραγωγα οξαζολυλ-μεθυλαιθερα ως αγωνιστες υποδοχεα alx

Country Status (19)

Country Link
US (1) US8846733B2 (el)
EP (1) EP2649068B1 (el)
JP (1) JP5923107B2 (el)
KR (1) KR101864463B1 (el)
CN (1) CN103261194B (el)
AR (1) AR084173A1 (el)
AU (1) AU2011340146B2 (el)
CA (1) CA2816376C (el)
CY (1) CY1116004T1 (el)
DK (1) DK2649068T3 (el)
ES (1) ES2526132T3 (el)
HR (1) HRP20150049T1 (el)
MX (1) MX2013006418A (el)
PL (1) PL2649068T3 (el)
PT (1) PT2649068E (el)
RU (1) RU2588567C2 (el)
SI (1) SI2649068T1 (el)
TW (1) TWI523853B (el)
WO (1) WO2012077049A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221392B (zh) 2010-11-17 2015-06-03 埃科特莱茵药品有限公司 桥联螺[2.4]庚酯衍生物
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
EP2850058B1 (en) 2012-05-16 2016-07-13 Actelion Pharmaceuticals Ltd. 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
JP6330038B2 (ja) 2013-07-18 2018-05-23 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ａｌｘ受容体アゴニストとしてのピペラジン置換架橋スピロ［２．４］ヘプタン誘導体
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
JP6453231B2 (ja) 2013-11-28 2019-01-16 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
WO2016189876A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
EP3303284B1 (en) 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
WO2018161175A1 (en) * 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
SI3762380T1 (sl) 2018-03-05 2022-09-30 Bristol-Myers Squibb Company Receptor agonisti fenilpirolidinon peptida 2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
US20040043904A1 (en) 2000-09-22 2004-03-04 Hiroshi Yamaguchi N-(4-pyrazolyl) amide derivatives, chemicals for agricultural and horticultural use, and usage of the same
US20050164305A1 (en) 2002-04-03 2005-07-28 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
WO2005047899A2 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
BRPI0511510A (pt) * 2004-05-25 2007-12-26 Metabolex Inc composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo
WO2007055941A2 (en) 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
KR101599715B1 (ko) 2007-08-21 2016-03-08 세노믹스, 인코포레이티드 인간 ｔ2ｒ 쓴맛 수용체 및 이의 용도
AR069650A1 (es) * 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
TWI434685B (zh) * 2007-12-18 2014-04-21 Actelion Pharmaceuticals Ltd 胺基三唑衍生物
BRPI1013083A2 (pt) 2009-05-18 2016-04-05 Actelion Pharmaceuticals Ltd derivados de espiro [2.4] heptano ligados como agonistas fprl2 e/ou recetor alx
CN101909306A (zh) * 2009-06-08 2010-12-08 中兴通讯股份有限公司 中继站管理方法及基站
EP2440555B1 (en) 2009-06-09 2016-05-18 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives
EP2440536B1 (en) * 2009-06-12 2013-11-06 Actelion Pharmaceuticals Ltd. Oxazole and thiazole derivatives as ALX receptor agonists
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物

Also Published As

Publication number Publication date
JP2013544878A (ja) 2013-12-19
CN103261194B (zh) 2016-02-24
RU2588567C2 (ru) 2016-07-10
AU2011340146B2 (en) 2016-05-19
PT2649068E (pt) 2014-12-23
MX2013006418A (es) 2013-07-15
HRP20150049T1 (hr) 2015-02-27
TW201305151A (zh) 2013-02-01
KR20130133240A (ko) 2013-12-06
AU2011340146A1 (en) 2013-07-25
CA2816376A1 (en) 2012-06-14
RU2013130879A (ru) 2015-01-20
ES2526132T3 (es) 2015-01-07
US20130261159A1 (en) 2013-10-03
SI2649068T1 (sl) 2015-01-30
EP2649068A1 (en) 2013-10-16
AR084173A1 (es) 2013-04-24
PL2649068T3 (pl) 2015-03-31
TWI523853B (zh) 2016-03-01
CA2816376C (en) 2018-11-20
KR101864463B1 (ko) 2018-06-04
EP2649068B1 (en) 2014-10-29
JP5923107B2 (ja) 2016-05-24
WO2012077049A1 (en) 2012-06-14
DK2649068T3 (en) 2014-12-08
US8846733B2 (en) 2014-09-30
CN103261194A (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
CY1116004T1 (el) Παραγωγα οξαζολυλ-μεθυλαιθερα ως αγωνιστες υποδοχεα alx
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1119953T1 (el) Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις
CY1120073T1 (el) Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2
CY1119762T1 (el) C-17-ετεροαρυλικα παραγωγα ελαιολικου οξεος και μεθοδοι χρησης αυτων
CY1117638T1 (el) Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1116984T1 (el) ΠΑΡΑΓΩΓΑ [1,2,3]ΤΡΙΑΖΟΛΟ[4,5-d]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ ΚΑΝΝΑΒΙΝΟΕΙΔΩΝ 2
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου
CY1115301T1 (el) Παραγωγα ισοξαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου
CY1114759T1 (el) Παραγωγα πυριδιν-4-υλι0υ ως s1p1/edg1 αγωνιστες
CY1115863T1 (el) Ενωσεις τριαζολοπyριδινης
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
CY1113422T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
CY1116741T1 (el) Νεοι συνδετες του υποδοχεα των οιστρογονων
CY1120378T1 (el) Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης)
CY1116439T1 (el) Τριαζολοπυριδινες
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
MX391724B (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
CY1121089T1 (el) Χρηση των παραγωγων της βενζιμιδαζολης-προλινης